Elicio Therapeutics, Inc. Common Stock
ELTXElicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies that stimulate the body’s immune system to fight cancer. Their platform utilizes particulate vaccines designed to target and activate immune cells, aiming to improve the effectiveness of cancer treatments and address unmet medical needs in oncology.
Company News
Elicio Therapeutics granted 22,400 inducement stock options to two new employees on January 15, 2026, at an exercise price of $7.81 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting ratably monthly thereafter.
Elicio Therapeutics appointed Marc J. Wolfgang as Chief Technology Officer, bringing over 30 years of biopharmaceutical leadership experience to strengthen the company's late-stage and commercial readiness for its immunotherapy pipeline.
Elicio Therapeutics announced successful results for its ELI-002 off-the-shelf cancer vaccine, which induced mKRAS-specific T cell responses in 99% of evaluable patients. The vaccine targets common KRAS mutations in solid tumors and showed promising survival outcomes in pancreatic and colorectal cancer patients.
Elicio Therapeutics published extended follow-up data for its ELI-002 cancer vaccine, showing promising results in treating minimal residual disease-positive patients with pancreatic and colorectal cancers, with significant reductions in death and relapse risks.
Elicio Therapeutics, a clinical-stage biotechnology company, will host a virtual event on June 25, 2025, to discuss its lead product candidate, ELI-002, an AMP-powered therapeutic vaccine for the treatment of KRAS mutation-driven pancreatic cancer. The event will feature insights from leading experts in the field.
